<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82738">
  <stage>Registered</stage>
  <submitdate>9/04/2008</submitdate>
  <approvaldate>11/04/2008</approvaldate>
  <actrnumber>ACTRN12608000189325</actrnumber>
  <trial_identification>
    <studytitle>Does starting children on an insulin pump improve how blood vessels work due to less variable blood glucose levels?</studytitle>
    <scientifictitle>Does commencing a continuous subcutaneous insulin infusion reduce glucose variability and improve vascular function in children with type 1 diabetes.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>type I diabetes</healthcondition>
    <healthcondition>cardiovascular disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>continuous subcutaneous insulin infusion (insulin pump), dose at calculated based on normal insulin requirements, study to continue for 3 weeks but patients to continue on insulin pump after study is complete</interventions>
    <comparator>Comparator will be the patient's normal subcutaneous insulin regimen prior to commencing on the insulin pump. Insulin dose and number of injections will be dependent on the need of the individual.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Glucose variability. Glucose variability will be assessed by using a Medtronic Minimed Paradigm Real-Time continuous glucose monitoring system (CGMS).</outcome>
      <timepoint>just prior and then 3 weeks after commencing an insulin pump</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Vascular function. Vascular endothelial function will be assessed using flow-mediated dilatation (FMD).</outcome>
      <timepoint>Just prior and then 3 weeks after commencing an insulin pump</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>vascular risk factors - venous blood test for : HbA1c, fasting lipids and glucose, hsCRP, adiponectin</outcome>
      <timepoint>just prior and then 3 weeks after commencing an insulin pump</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children with type I diabetes from the diabetes clinic at the Adelaide Chidren, Youth and Women's Health Service on the waiting list to commence an insulin pump</inclusivecriteria>
    <inclusiveminage>8</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>smoking, history of allergic reaction to nitrates or nitrites, pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Subjects will have glucose variability and vascular function assessed prior and then 3 weeks after commencing an insulin pump</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>18/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Adelaide Children, Youth abd Women's Health Service</primarysponsorname>
    <primarysponsoraddress>72 King William Road
North Adelaide</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Adelaide Children, Youth and Women's Health Service</fundingname>
      <fundingaddress>72 King William Road
North Adelaide</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Pfizer Australia Paediatric Endocrine Care Grant</fundingname>
      <fundingaddress>APEC Research Grants
PO BOX 57
West Ryde NSW 2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Pfizer Australia Paediatric Endocrine Care Grant</sponsorname>
      <sponsoraddress>APEC Research Grants
PO BOX 57</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We already know that blood glucose levels relate to the long term vascular complications in type I diabetes. There have been other studies that suggest that blood glucose variability (i.e. how much the blood glucose levels vary through the day) may also be an important factor. The purpose of this study is to look at blood vessel function and glucose variability in children whilst they are on insulin injections compared with shortly after starting an insulin pump. 
The hypotheses to be tested are: 
Commencing children with type I diabetes on a insulin pump improves how blood vessels work
Commencing children with type I diabetes on a insulin pump reduces glucose variability
The improvement in how the blood vessels is due to reduced glucose variability independent of other changes in vascular risk factors.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Adelaide Children, Youth and Women's Health Service Research Ethics Committee</ethicname>
      <ethicaddress>72 King William Road
North Adelaide SA 5006</ethicaddress>
      <ethicapprovaldate>2/04/2008</ethicapprovaldate>
      <hrec>REC2032/2/11</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jennifer Harrington</name>
      <address>72 King William Road
North Adelaide SA 5006</address>
      <phone>08 8161402</phone>
      <fax>08 81617759</fax>
      <email>jennifer.harrington@cywhs.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jennifer Harrington</name>
      <address>72 King William Road
North Adelaide SA 5006</address>
      <phone>08 81616402</phone>
      <fax>08 81617759</fax>
      <email>jennifer.harrington@cywhs.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jennifer Harrington</name>
      <address>72 King William Road
North Adelaide SA 5006</address>
      <phone>08 8161402</phone>
      <fax>08 81617759</fax>
      <email>jennifer.harrington@cywhs.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>